Immunotherapy Transforms Melanoma Survival Rates

Ten-year clinical trial results show durable survival and the possibility of cure in advanced melanoma

Immune checkpoint inhibitors have redefined melanoma care. Results from the landmark CheckMate 067 trial show that nearly half of patients treated with nivolumab plus ipilimumab were alive at 10 years, compared with less than one-quarter of those receiving ipilimumab alone.